Le Lézard
Classified in: Health, Science and technology, Business
Subjects: FNC, TRI

BRAINBox Solutions Announces Initial Series B Investments to Support U.S. Regulatory Clearance, Initial Commercialization of BRAINBox TBI Concussion Diagnostic/Prognostic Test


RICHMOND, Va., Oct. 30, 2023 /PRNewswire/ -- BRAINBox Solutions today announced initial investments into the company's Series B financing to support U.S. regulatory clearance and initial commercialization of its BRAINBox TBI concussion diagnostic/prognostic test in adults and completion of a clinical study in pediatric patients. Genoa Ventures is leading the financing, which includes other current and new investors.

"We have made significant clinical and pre-commercial progress in developing the BRAINBox TBI test," said Donna Edmonds, BRAINBox Solutions' CEO. "We are working with selected platform partners as we determine the fastest path to market for use in both point-of-care and emergency department settings." She noted that in addition to the adult population, the company is developing BRAINBox TBI tests for pediatric patients, and, through a National Institutes of Health grant, for geriatric patients.

"The BRAINBox TBI test is the first to integrate physiologic and functional testing, an approach that is designed to maximize sensitivity and specificity, and provide objective criteria for the diagnosis and prognosis of acute traumatic encephalopathy, commonly known as concussion," said W. Frank Peacock, MD FACEP, FACC, FESC, the study's Principal Investigator and Professor, Vice Chair for Research, Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine.

The company's key progress and achievements include:

HeadSMART II trial ? The pivotal trial to support FDA clearance in adults has enrolled 2000 subjects, including subjects for the company's Normative Data Base in support of the Neurocognitive Component of the Multi-Marker Multi-Modality Product. The company has presented its clinical data at several medical meetings over the past several months.

Pediatric Test ? The company entered a funded collaboration with USA Hockey, to evaluate biomarkers in blood and saliva for concussion in elite girls and boys high school hockey players. The study aims to add to the information in the development of the company's pediatric test by providing objective evidence of neurocognitive changes due to head impacts. The company's pilot clinical trial in pediatric subjects is currently underway.

"In the current healthcare environment, where priorities include appropriate resource utilization, timely value-based care and patient satisfaction, both patients and clinicians strongly desire a quantitative approach that guides the next step in concussion management," commented Chad Cannon MD, Chair & Clinical Service Chief, Professor, Department of Emergency Medicine at University of Kansas Medical Center and The University of Kansas Health System, and a Principal Investigator for the HeadSMART II trial.

About BRAINBox Solutions
BRAINBox Solutions, Inc is developing the first AI?enabled, multi?modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, commonly referred to as a concussion. The company seeks to establish a clinical best?practice standard for the diagnosis and prognosis of concussion. The company also has a portfolio of biomarkers that reflect neurological changes and will be applicable in chronic disease. The product incorporates a panel of proprietary, patented blood biomarkers that can be read in a few moments on a point?of?care instrument or using standard laboratory systems, as well as neurocognitive testing, to provide a single?system score that measures the severity of the injury and post-concussive symptoms. The company is led by key physician and scientific thought leaders in the field and an experienced, clinically focused management team. Learn more at: www.brainboxinc.com

For more information, contact:
Donna Edmonds
CEO
1?804?724?0009

SOURCE BRAINBox Solutions, Inc.


These press releases may also interest you

at 08:15
Lantern Pharma Inc. , a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW. The conference will be on Thursday, March 7th, and is a virtual event. Lantern...

at 08:15
Mirum Pharmaceuticals, Inc. , a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the...

at 08:15
Vir Biotechnology, Inc. today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed...

at 08:15
Tevogen Bio Holdings ('Tevogen Bio') , congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director of Risk Advisory Services at Verita CSG, Inc., a provider of holistic insurance and risk management solutions for...

at 08:15
Nielsen BioSciences, Inc. ("Nielsen"), a privately-held, San Diego-based biopharmaceutical company, today announced the first patient enrolled in CFW-3A ? a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of...

at 08:15
SENA Health announces its partnership with Inspira Health to support patients receiving Healing at Home clinical services. The home-based services deliver advanced-level care to eligible Inspira Health patients in the comfort of their own homes. The...



News published on and distributed by: